Antech Diagnostics’ Post

🔍🐾 Early cancer detection just got a game-changer! Learn how the Onconeural High-Risk Antibody Test is transforming early diagnostics in pets, offering new hope for proactive care. Discover its impact on veterinary oncology in our latest blog! Pet Preferred Diagnostics, LLC https://lnkd.in/eJ5pzgEw #VetOncology #PetCancerCare #EarlyDiagnostics

Check out our new blog post, "Autologous Cancer Vaccines in the Era of Personalized Medicine," in which we discuss recent advances in ACV technology, applications of ACVs to veterinary oncology, and more! Read here: https://hubs.li/Q02tNLHr0

Two years ago, FidoCure® and Thrive Pet Healthcare joined forces to bring the patented FidoCure precision medicine platform to veterinarians across the Thrive network. Today, I'm proud to share the incredible impact of our partnership: • 400+ canine cancer cases treated in the initial phase • 25% year-over-year growth from the Thrive network • 5,000+ dogs treated with FidoCure's precision medicine platform But beyond the numbers, we’re seeing the ripple effect of our work. Through our patented novel approach and cutting-edge genomic sequencing, these canine cancer warriors are contributing to advancements in human cancer research. As we grow into our next phase of AI-driven drug development, we're not just fighting cancer in pets – we're crushing cancer on both sides of the leash. Here's to two years of lifesaving collaboration! Click below for the full story, featuring Venya, a 13½-year-old German Shepherd who inspires us to push the boundaries of veterinary oncology as she thrives despite multiple cancer diagnoses. https://hubs.li/Q02QC0840

Ask your vet if NuQ can help your dog by offering early detection of cancer.

Join us for "Bridging the Gap: What Oncologists Wish GPs Knew About Veterinary Oncology," sponsored by Pet Cancer Care Consulting. 🩺🐾 This insightful session is designed to help general practitioners better understand key aspects of oncology, from handling masses and diagnostic testing to staging and treatment options. 👨🏫 Learning Objectives: -Best practices for approaching masses -Updates on diagnostic testing to obtain accurate diagnoses -Staging cancer and its impact on treatment decisions -How GPs and oncologists can collaborate more effectively -What oncologists need before referral Don't miss this opportunity to improve your veterinary oncology knowledge and enhance GP-specialist collaboration! 👉 Register here: https://lnkd.in/eSaTe9Sp #VetOncology #VetCPD #PetCancerCare #TheWebinarVet #GPsAndSpecialists

You found a lump on Fluffy. Historically you may proceed with an FNA, or discuss surgical options with your client. What if you could offer a test which would tell you in less than a minute whether the lump is cancerous or benign? Covetrus and HT Vista are now bringing you the ability to offer this 3rd option to your clients. “The HT Vista gives pet parents peace of mind with a simple 40 second scan. It is completely non-invasive, affordable, and can screen masses without the need to aspirate or biopsy.” Contact me today to implement this revolutionary new technology to your veterinary practice! #veterinary #Covetrus #vetmed #KeepThriving #HTVista #cancer #cancerscreening

Our veterinary oncologists are here to replace the misconceptions and fear with knowledge and hope. We strive to provide you with accurate, in-depth information regarding a pet’s cancer and treatment options. For the full context behind these listed pet cancer myths and truths, visit our Pet Cancer Awareness Month blog: https://lnkd.in/gbJayhiZ #petcancerawarenessmonth #momentsmatter #vetmedicine #vetspeciality #vetspecialists

FidoCure will present important new findings on canine hemangiosarcoma (HSA) at the 2024 Veterinary Cancer Society (VCS) Annual Conference, October 17-19 at the Caribe Royale Orlando! This marks our continued leadership in the largest and most prestigious conference in the veterinary oncology field. Canine splenic hemangiosarcoma, a particularly aggressive cancer that originates in the spleen, is responsible for approximately 300,000 dog deaths annually in the U.S. At the conference, Dr. Lucas Rodrigues, FidoCure's Head of Veterinary Research, will unveil our latest findings on HSA. The study demonstrates that AI-driven precision oncology for dogs with splenic hemangiosarcoma yields outcomes that are comparable to, or even exceed, those achieved with standard adjuvant chemotherapy. Furthermore, we have pinpointed specific genetic mutations that are closely linked to prognosis, significantly advancing our understanding of canine HSA. Visit us at Booth 25 to learn how our data-driven approach and innovative therapies are enhancing treatment outcomes and quality of life for dogs with cancer. Discover how we're elevating the standard of care in veterinary oncology and developing first-class precision therapies for canine cancer. Learn more about the research. https://bwnews.pr/4eLGQYR #VeterinaryOncology #CanineCancer #PrecisionMedicine #VCS2024 #VeterinaryCancerSociety #FidoCure #Hemangiosarcoma

Mark your calendars for “If You’re Not Seeing Canine Lymphoma Patients, They Might Be Seeing You!” presented by Dr. Natalie Marks, DVM, CVJ, on Thursday, May 16, at 7:00 p.m. EDT. In this presentation, Dr. Marks will begin with a quick review of the prevalence of canine lymphoma and why early diagnosis is critical. The bulk of the lecture will focus on five critical areas the veterinary team can focus on for earlier diagnostics and education for pet owners. These include identifying at-risk breeds, questions to ask when taking the patient’s history, commonly missed clinical signs, subtle physical exam findings that dictate further diagnostics, and recommended workup options (including the spectrum of care.) The final sections of this presentation will discuss how to utilize resources for efficient and effective communication in your practice. 🗓️ Date: Thursday, May 16, 2024 🕒 Time: 7:00 p.m. EDT Register now to secure your spot: https://brnw.ch/21wJCvW

I am thrilled to share that the article titled “Relative Tumour Volume in Canine Oral Melanoma Staging and Prognosis" has been published in Veterinary and Comparative Oncology journal! 🎉 In this retrospective study regarding Canine Oral Melanoma, we explored the staging and prognostic value of a tumor ratio instead of absolute tumor volume alone, since dogs have a vast phenotypic diversity.  This study was a result of a collaboration between the Faculties of Veterinary Medicine from University of Lisbon, in Portugal, and Universities of Parma and Torino, in Italy. I hope this study contributes to the ongoing conversation about how certain clinical variables can impact Canine Oral Melanoma prognosis and how we can manage them to better treat these patients. A huge thank you to all authors: Inês Martinho, Margarida Rocha, Marina Martano, Kevin P. Spindler, Paolo Buracco, Davide Giacobino, Helena Florindo and Lisa Mestrinho, for their invaluable work, collaboration and help throughout this journey! 💪 I invite you all to read it and share your thoughts! DOI: https://lnkd.in/dbR7AZd5 #Melanoma #Research #CanineCancer #VeterinaryMedicine